BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28444771)

  • 1. Oestrone-targeted liposomes for mitoxantrone delivery via oestrogen receptor - synthesis, physicochemical characterization and in-vitro evaluation.
    Hao Q; Xu G; Yang Y; Sun Y; Cong D; Li H; Liu X; Wang Z; Zhang Z; Chen J; Li Y; Luan X; Wang L; Tian L; Liu K; Li Y; Jiao Q; Pei J
    J Pharm Pharmacol; 2017 Aug; 69(8):991-1001. PubMed ID: 28444771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrone-targeted liposomes for mitoxantrone delivery via estrogen receptor: In vivo targeting efficacy, antitumor activity, acute toxicity and pharmacokinetics.
    Xu G; Tang H; Chen J; Zhu M; Xie Y; Li Y; Hao Q; Sun Y; Cong D; Meng Q; Ren Z; Li Q; Bao H; Lv Z; Li Y; Pei J
    Eur J Pharm Sci; 2021 Jun; 161():105780. PubMed ID: 33667664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer.
    Tang H; Chen J; Wang L; Li Q; Yang Y; Lv Z; Bao H; Li Y; Luan X; Li Y; Ren Z; Zhou X; Cong D; Liu Z; Jia J; Chen H; Zhao W; Meng Q; Sun F; Pei J
    Int J Pharm; 2020 Jan; 573():118806. PubMed ID: 31678519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrone-targeted PEGylated Liposomal Nanoparticles for Cisplatin (DDP) Delivery in Cervical Cancer.
    Li Q; Zhu M; Li Y; Tang H; Wang Z; Zhang Y; Xie Y; Lv Z; Bao H; Li Y; Liu R; Shen Y; Zheng Y; Miao D; Guo X; Pei J
    Eur J Pharm Sci; 2022 Jul; 174():106187. PubMed ID: 35430381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo Evaluation of a Novel Estrogen-Targeted PEGylated Oxaliplatin Liposome for Gastric Cancer.
    Sun Y; Xie Y; Tang H; Ren Z; Luan X; Zhang Y; Zhu M; Lv Z; Bao H; Li Y; Liu R; Shen Y; Zheng Y; Pei J
    Int J Nanomedicine; 2021; 16():8279-8303. PubMed ID: 34992365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.
    He Y; Zhang L; Song C
    Int J Nanomedicine; 2010 Sep; 5():697-705. PubMed ID: 20957221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer.
    Xie Y; Ren Z; Chen H; Tang H; Zhu M; Lv Z; Bao H; Zhang Y; Liu R; Shen Y; Zheng Y; Miao D; Guo X; Chen H; Wang S; Pei J
    Biomed Pharmacother; 2023 Apr; 160():114304. PubMed ID: 36724638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.
    Gokhale PC; Pei J; Zhang C; Ahmad I; Rahman A; Kasid U
    Anticancer Res; 2001; 21(5):3313-21. PubMed ID: 11848489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model.
    Cordeiro Pedrosa LR; van Tellingen O; Soullié T; Seynhaeve AL; Eggermont AM; Ten Hagen TL; Verheij M; Koning GA
    Eur J Pharm Biopharm; 2015 Aug; 94():207-19. PubMed ID: 25982691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide.
    Zhang L; Ren Y; Wang Y; He Y; Feng W; Song C
    Int J Nanomedicine; 2018; 13():1097-1105. PubMed ID: 29520138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro.
    Tang H; Zhang Z; Zhu M; Xie Y; Lv Z; Liu R; Shen Y; Pei J
    Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oestrogen receptor-mediated liposomal drug delivery for treating melanoma.
    Ganguly A; Rachamalla HKR; Bhattacharya D; Bhamidipati K; Pal A; Gora Ravuri H; Chakravarty S; Adhikari SS; Banerjee R
    J Drug Target; 2018; 26(5-6):481-493. PubMed ID: 29376759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
    Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K; Sundaresan A; Cheow WS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-chain glycoceramides promote intracellular mitoxantrone delivery from novel nanoliposomes into breast cancer cells.
    Pedrosa LR; Ten Hagen TL; Süss R; van Hell A; Eggermont AM; Verheij M; Koning GA
    Pharm Res; 2015 Apr; 32(4):1354-67. PubMed ID: 25319103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
    Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
    PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
    Schwendener RA; Fiebig HH; Berger MR; Berger DP
    Cancer Chemother Pharmacol; 1991; 27(6):429-39. PubMed ID: 2013113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice].
    Chen T; Hou SX; Wang YY; Zhang WS; Chen DH
    Yao Xue Xue Bao; 2006 Dec; 41(12):1170-5. PubMed ID: 17290615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation.
    Nallamothu R; Wood GC; Pattillo CB; Scott RC; Kiani MF; Moore BM; Thoma LA
    AAPS PharmSciTech; 2006 Apr; 7(2):E32. PubMed ID: 16796350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.